# Puyuan Xing

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/puyuan-xing/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,005 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 29 |
| i10-index | 77 |
| Last Known Institution | Chinese Academy of Medical Sciences & Peking Union Medical College |
| OpenAlex ID | https://openalex.org/A5030376299 |
| ORCID iD | 0000-0003-4415-9892 |
| Works | 279 |

## Researcher papers

Showing 12 of 13.

- [Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer](https://scholariq.org/papers/phase-i-study-and-biomarker-analysis-of-pyrotinib-a-novel-irreversible-pan-erbb/)
- [Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis](https://scholariq.org/papers/incidence-rates-of-immune-related-adverse-events-and-their-correlation-with/)
- [Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey](https://scholariq.org/papers/clinical-characteristics-and-medical-service-utilization-of-lung-cancer-in-china/)
- [Current management of chemotherapy-induced neutropenia in adults: key points and new challenges](https://scholariq.org/papers/current-management-of-chemotherapy-induced-neutropenia-in-adults-key-points-and/)
- [Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial](https://scholariq.org/papers/safety-efficacy-and-biomarker-analysis-of-pyrotinib-in-combination-with/)
- [What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China](https://scholariq.org/papers/what-are-the-clinical-symptoms-and-physical-signs-for-non-small-cell-lung-cancer/)
- [A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy](https://scholariq.org/papers/a-phase-ii-study-of-biweekly-paclitaxel-and-cisplatin-chemotherapy-for-recurrent/)
- [Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants](https://scholariq.org/papers/response-to-crizotinib-in-advanced-alk-rearranged-non-small-cell-lung-cancers/)
- [Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes](https://scholariq.org/papers/acquired-resistance-to-osimertinib-in-patients-with-non-small-cell-lung-cancer/)
- [Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)](https://scholariq.org/papers/sintilimab-versus-docetaxel-as-second-line-treatment-in-advanced-or-metastatic/)
- [Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma](https://scholariq.org/papers/comprehensive-analysis-of-treatment-modes-and-clinical-outcomes-of-small-cell/)
- [685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China](https://scholariq.org/papers/685p-genomic-profiles-in-egfr-mutant-locally-advanced-or-metastatic-nsclc/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Chinese Academy of Medical Sciences & Peking Union Medical College](https://scholariq.org/institutions/chinese-academy-of-medical-sciences-and-peking-union-medical-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.